These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 33216643)

  • 1. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.
    Talamonti M; Galluzzo M; Chiricozzi A; Quaglino P; Fabbrocini G; Gisondi P; Marzano AV; Potenza C; Conti A; Parodi A; Piaserico S; Bardazzi F; Argenziano G; Rongioletti F; Stingeni L; Micali G; Loconsole F; Rossi MT; Bongiorno MR; Feliciani C; Rubegni P; Amerio P; Fargnoli MC; Pigatto P; Savoia P; Nisticò SP; Giustini S; Carugno A; Cannavo' SP; Rech G; Prignano F; Offidani A; Lombardo M; Zalaudek I; Bianchi L; Peris K; ; Balestri R ; Bernardini N ; Belloni Fortini A ; Burlando M ; Caldarola G ; Campione E ; Cattaneo A ; Dapavo P ; Dastoli S ; De Simone C ; Di Nuzzo S ; Diotallevi F ; Fierro MT ; Franchi C ; Esposito M ; Foti C ; Gambini DM ; Gambardella A ; Girolomoni G ; Giunta A ; Guarneri C ; Gualdi G ; Hansel K ; Megna M ; Mugheddu C ; Musumeci ML ; Patrizi A ; Pellacani G ; Richetta AG ; Rosi E ; Sacchelli L ; Tiberio R ; Tilotta G ; Trovato E ; Venturini M ; Vezzoni R
    Expert Opin Biol Ther; 2021 Feb; 21(2):271-277. PubMed ID: 33216643
    [No Abstract]   [Full Text] [Related]  

  • 2. The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.
    Ciechanowicz P; Dopytalska K; Mikucka-Wituszyńska A; Dźwigała M; Wiszniewski K; Herniczek W; Szymańska E; Walecka I
    J Dermatolog Treat; 2022 May; 33(3):1581-1584. PubMed ID: 33317364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
    Galluzzo M; Tofani L; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2020 Aug; 20(8):829-830. PubMed ID: 32510244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.
    Gisondi P; Piaserico S; Naldi L; Dapavo P; Conti A; Malagoli P; Marzano AV; Bardazzi F; Gasperini M; Cazzaniga S; Costanzo A;
    J Allergy Clin Immunol; 2021 Feb; 147(2):558-560.e1. PubMed ID: 33160968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 and psoriasis: biologic treatment and challenges.
    Ebrahimi A; Sayad B; Rahimi Z
    J Dermatolog Treat; 2022 Mar; 33(2):699-703. PubMed ID: 32598204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
    Polat Ekinci A; Pehlivan G; Gökalp MO
    Dermatol Ther; 2021 Jan; 34(1):e14700. PubMed ID: 33369063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis.
    Gisondi P; Geat D; Bellinato F; Girolomoni G
    Expert Opin Biol Ther; 2022 Dec; 22(12):1521-1529. PubMed ID: 35930356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
    Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
    J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone.
    Brazzelli V; Isoletta E; Barak O; Barruscotti S; Vassallo C; Giorgini C; Michelerio A; Tomasini CF; Musella V; Klersy C
    Dermatol Ther; 2020 Nov; 33(6):e14516. PubMed ID: 33169500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].
    Ladda M; Lynde C; Fleming P
    J Cutan Med Surg; 2020; 24(6):625-632. PubMed ID: 32757760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.
    Damiani G; Pacifico A; Bragazzi NL; Malagoli P
    Dermatol Ther; 2020 Sep; 33(5):e13475. PubMed ID: 32356577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic drugs during COVID-19 outbreak.
    Montesu MA; Biondi G; Sotgiu G; Sucato F; Satta R
    Int J Dermatol; 2020 Oct; 59(10):1293. PubMed ID: 32767379
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).
    Kwee KV; Murk JL; Yin Q; Visch MB; Davidson L; de Jong EMGJ; van den Reek JMPA; Tjioe M
    J Dermatolog Treat; 2023 Dec; 34(1):2161297. PubMed ID: 36545844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.
    Ghoreishi Amin N; Khosravi S; Atefi N; Seirafianpour F; Farhoodi S; Goodarzi A
    Immun Inflamm Dis; 2023 Nov; 11(11):e1063. PubMed ID: 38018599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the COVID-19 pandemic on biologic treatment in psoriasis patients: A single-center retrospective study in Japan.
    Uchida H; Kamata M; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2022 Jun; 49(6):624-628. PubMed ID: 35319126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy.
    Piaserico S; Gisondi P; Cazzaniga S; Naldi L
    Am J Clin Dermatol; 2020 Oct; 21(5):749-751. PubMed ID: 32812188
    [No Abstract]   [Full Text] [Related]  

  • 18. How lockdown measures, during COVID-19 pandemic, matter on psoriatic patient's perception: Study on 600 patients on biologic therapy.
    Bernardini N; Skroza N; Spagnoli A; Marchesiello A; Balduzzi V; Tolino E; Mambrin A; Michelini S; Maddalena P; Volpe S; Proietti I; Vestri A; Potenza C
    J Infect Public Health; 2021 Jul; 14(7):878-882. PubMed ID: 34118738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course.
    Yalici-Armagan B; Tabak GH; Dogan-Gunaydin S; Gulseren D; Akdogan N; Atakan N
    J Cosmet Dermatol; 2021 Oct; 20(10):3098-3102. PubMed ID: 34365714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.